BH
BHVN.US Biohaven Ltd.
- Market cap
- USD 2.09B
- P/E
- -
- P/B
- 203.79x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BHVN.US undervalued?
Graham numberThe Graham number of Biohaven Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biohaven Ltd. fundamental analysis
No fundamental analysis for Biohaven Ltd. yet.
Biohaven Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biohaven Ltd.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that …
Full company profileBiohaven Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biohaven Ltd. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | - | 0.00 | 463M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | -72.0K | 371M | -1.39M | -3.37M | -3.92M | -4.14M | - |
| Operating Income | - | -479M | -115M | -219M | -568M | -436M | -885M | -745M | -509M |
| EBITDA | - | -479M | -114M | -211M | -568M | -403M | -838M | -727M | -520M |
| Net Income | - | -529M | -119M | -214M | -570M | -408M | -846M | -739M | -529M |
| EPS | - | -11 | -3.01 | -5.43 | -13 | -5.73 | -9.28 | -6.86 | -3.51 |
| Balance Sheet | |||||||||
| Total Assets | 147M | 344M | 111M | 142M | 662M | 513M | 615M | 451M | 264M |
| Total Liabilities | 14.9M | 352M | 34.7M | 47.4M | 123M | 85.2M | 192M | 399M | 362M |
| Shareholders' Equity | 132M | -7.42M | 76.8M | 94.7M | 539M | 428M | 423M | 52.1M | -98.2M |
| Cash & Short-term Investments | 131M | 317M | 82.5M | 76.1M | 465M | 382M | 486M | 319M | 161M |
| Total Debt | - | - | 267M | 627M | 33.6M | 30.9M | 36.6M | 285M | 300M |
| Cash Flow | |||||||||
| Operating Cash Flow | -94.8M | -377M | -76.0M | -146M | -298M | -332M | -582M | -609M | -456M |
| Capital Expenditure | 541K | 2.53M | 2.70M | 938K | 41.1M | 3.05M | 4.05M | 715K | 845K |
| Free Cash Flow | -95.4M | -380M | -78.7M | -147M | -339M | -335M | -587M | -610M | -457M |
| Ratios | |||||||||
| ROE | - | - | -154.6% | -225.8% | -105.8% | -95.4% | -199.9% | -1,418.8% | - |
| ROA | - | -153.6% | -106.4% | -150.5% | -86.2% | -79.5% | -137.6% | -163.7% | -200.8% |
| Net Profit Margin | - | - | - | -46.2% | - | - | - | - | - |
| Debt to Equity | - | - | 3.48x | 6.62x | 0.06x | 0.07x | 0.09x | 5.47x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biohaven Ltd. dividends
Biohaven Ltd. has not paid dividends in the last 9 fiscal years.
Who owns Biohaven Ltd.
- Insiders 11.20%
- Institutions 88.80%
- Public & others 0.00%
- Shares outstanding 151M
- Free float 117M
Top funds holding BHVN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 3.97M | 2.63% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 3.39M | 2.24% | 0.00% | Oct 2026 |
| Fidelity Select Biotechnology | 2.18M | 1.44% | 0.00% | Aug 2026 |
| HBM Healthcare Investments AG Ord | 1.94M | 1.28% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 1.47M | 0.97% | +0.59% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 1.25M | 0.83% | -0.38% | Oct 2026 |
| American Funds SMALLCAP World A | 1.17M | 0.77% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 1.00M | 0.66% | -0.19% | Oct 2026 |
| T. Rowe Price Health Sciences | 941K | 0.62% | 0.00% | Sep 2026 |
| Janus Henderson Glb Life Scn I2 USD | 910K | 0.60% | -22.39% | Aug 2026 |
| Janus Henderson Global Life Sciences D | 851K | 0.56% | -10.92% | Sep 2026 |
| Nuveen Quant Small Cap Equity R6 | 826K | 0.55% | 0.00% | Aug 2026 |
| Janus Global Life Science AUSD | 820K | 0.54% | -35.61% | Sep 2026 |
| Vanguard Russell 2000 ETF | 775K | 0.51% | +1.04% | Sep 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 770K | 0.51% | -52.55% | Jun 2026 |
| CREF Total Global Stock Account R3 | 707K | 0.47% | -7.44% | Aug 2026 |
| Schwab US Small-Cap ETF™ | 656K | 0.43% | +0.24% | Oct 2026 |
| Simplify Health Care ETF | 517K | 0.34% | +3.04% | Oct 2026 |
| Vanguard Strategic Equity Inv | 491K | 0.32% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 489K | 0.32% | -23.39% | Sep 2026 |
Top institutions holding BHVN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 13.2M | 8.75% | +17.72% | Jun 2026 |
| Suvretta Capital Management, LLC | 10.3M | 6.81% | 0.00% | Jun 2026 |
| Stifel Financial Corp | 9.94M | 6.58% | +0.00% | Jun 2026 |
| Jupiter Topco LLC | 8.58M | 5.68% | 0.00% | Jun 2026 |
| Woodline Partners LP | 7.66M | 5.07% | +2,450.12% | Jun 2026 |
| State Street Corp | 6.95M | 4.60% | +4.96% | Jun 2026 |
| D. E. Shaw & Co LP | 4.19M | 2.77% | +47.17% | Jun 2026 |
| AQR Capital Management LLC | 4.15M | 2.75% | +110.10% | Jun 2026 |
| Geode Capital Management, LLC | 3.32M | 2.20% | +20.07% | Jun 2026 |
| FMR Inc | 2.96M | 1.96% | +25.67% | Jun 2026 |
| Royalty Pharma Sub-Manager, LLC | 2.94M | 1.94% | 0.00% | Jun 2026 |
| Cormorant Asset Management, LLC | 2.61M | 1.73% | +48.30% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.58M | 1.71% | +2.78% | Jun 2026 |
| UBS Group AG | 2.52M | 1.67% | +76.58% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.49M | 1.65% | +9.20% | Jun 2026 |
| Balyasny Asset Management LLC | 1.88M | 1.24% | -23.13% | Jun 2026 |
| TCG Crossover Management, LLC | 1.78M | 1.18% | -61.57% | Jun 2026 |
| Nuveen, LLC | 1.74M | 1.15% | +133.90% | Jun 2026 |
| Rubric Capital Management LP | 1.72M | 1.14% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 1.62M | 1.07% | -6.00% | Jun 2026 |
Biohaven Ltd. company profile
- Company name
- Biohaven Ltd.
- Ticker
- BHVN.US
- ISIN
- VGG1110E1079
- Exchange
- USA Stocks
- Listed since
- Sep 23, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 274
- Fiscal year end
- December
- Address
- 215 Church Street, New Haven, CT, United States, 06510
- Phone
- 203 404 0410
- Website
- biohaven.com
About Biohaven Ltd.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Biohaven Ltd. management
10- Dr. Vladimir Coric M.D.Chairman & CEO · born 1971
- Mr. Matthew ButenChief Financial Officer · born 1961
- Ms. Kimberly GentileSenior Vice President of Clinical Operations · born 1966
- Dr. Bruce D. Car D.V.M., DACVP, Ph.D.Chief Innovation Officer · born 1962
- Ms. Deb YoungSenior Director of Regulatory Affairs & Operations
- Mr. George C. Clark CPAVP & Chief Accounting Officer · born 1985
- Mr. John McGillChief Technology Officer
- Ms. Jennifer PorcelliVice President of Investor Relations
- Mr. Warren Volles J.D.General Counsel & Chief Legal Officer
- Mr. Clifford Bechtold M.S.President & GM of Biohaven Ireland Chief Compliance Officer